» Authors » Kirsten Mundt

Kirsten Mundt

Explore the profile of Kirsten Mundt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 157
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, et al.
J Clin Oncol . 2023 Dec; 42(5):550-561. PMID: 38096461
Purpose: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier:...
2.
Konopleva M, Rollig C, Cavenagh J, Deeren D, Girshova L, Krauter J, et al.
Blood Adv . 2022 Apr; 6(14):4147-4156. PMID: 35413116
The phase 3 MIRROS (MDM2 antagonist Idasanutlin in Relapsed or Refractory acute myeloid leukemia [AML] for Overall Survival) trial (NCT02545283) evaluated the efficacy and safety of the small-molecule MDM2 antagonist...
3.
Pott C, Sehn L, Belada D, Gribben J, Hoster E, Kahl B, et al.
Leukemia . 2019 Aug; 34(2):522-532. PMID: 31462735
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus...
4.
Liu C, Powell K, Mundt K, Wu L, Carr A, Caspari T
Genes Dev . 2003 Apr; 17(9):1130-40. PMID: 12695334
The signalosome is implicated in regulating cullin-dependent ubiquitin ligases. We find that two signalosome subunits, Csn1 and Csn2, are required to regulate ribonucleotide reductase (RNR) through the degradation of a...